Equity Overview
Price & Market Data
Price: $11.33
Daily Change: +$0.36 / 3.18%
Daily Range: $10.76 - $11.65
Market Cap: $957,948,352
Daily Volume: 924,591
Performance Metrics
1 Week: -0.75%
1 Month: 4.23%
3 Months: 32.25%
6 Months: 25.45%
1 Year: 73.88%
YTD: 4.42%
Company Details
Employees: 42
Sector: Health technology
Industry: Biotechnology
Country:
Details
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases in the United States. The company's lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. It also provides ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. Anavex Life Sciences Corp. was incorporated in 2004 and is headquartered in New York, New York.